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Human group 1 ILCs consist of at least three pheno-
typically distinct subsets, including NK cells, CD127+
ILC1, and intraepithelial CD103+ ILC1. In inflamed
intestinal tissues from Crohn’s disease patients,
numbers of CD127+ ILC1 increased at the cost of
ILC3. Here we found that differentiation of ILC3 to
CD127+ ILC1 is reversible in vitro and in vivo.
CD127+ ILC1 differentiated to ILC3 in the presence
of interleukin-2 (IL-2), IL-23, and IL-1b dependent
on the transcription factor RORgt, and this process
was enhanced in the presence of retinoic acid.
Furthermore, we observed in resection specimen
from Crohn’s disease patients a higher proportion
of CD14+ dendritic cells (DC), which in vitro promoted
polarization from ILC3 to CD127+ ILC1. In contrast,
CD14 DCs promoted differentiation from CD127+
ILC1 toward ILC3. These observations suggest that
environmental cues determine the composition,
function, and phenotype of CD127+ ILC1 and ILC3
in the gut.
INTRODUCTION
The intestinal immune system is tolerant toward commensal
bacteria but adroitly poised to fight invading pathogens. Homeo-
static interactions between commensal bacteria and the intesti-
nal immune cells contribute to the surveillance of the mucosal
surface and maintenance of the epithelial barrier. Upon a patho-
genic assault, the innate immune system responds promptly by
tailoring an immune response accordingly to eliminate the path-
ogen or to instruct the adaptive arm of the immune system.
Following the mounted immune response, a phase of resolution
precedes the recovery of intestinal homeostasis and restoration
of the intestinal architecture.146 Immunity 43, 146–160, July 21, 2015 ª2015 Elsevier Inc.Innate lymphoid cells (ILCs) are a family of innate effector
cells that are important not only for the integrity and mainte-
nance of the intestinal tract but also in the protection against
infiltrating pathogens at the acute phase of infection (Artis
and Spits, 2015; Spits and Cupedo, 2012). Distinct ILC sub-
sets respond to and protect against different pathogens by
secreting cytokines that are similar to the cytokine and tran-
scription factor expression pattern of the T helper cell family
(Spits et al., 2012).
RORgt-expressing CD127+ group 3 ILCs are involved in orga-
nizing tertiary lymphoid structures (van de Pavert and Mebius,
2010), are critical in controlling containment of commensals
(Sonnenberg et al., 2012), and also promote antimicrobial pep-
tide production and the proliferation of epithelial cells (Cella
et al., 2009; Crellin et al., 2010). Furthermore, IL-22 producing
group 3 ILCs protect against certain bacterial pathogens such
as Citrobacter rodentium, which is used as a model in mice
for the attaching and effacing enteropathogenic Escherichia
coli (EPEC) and enterohaemorrhagic E. coli (EHEC) (Satoh-Ta-
kayama et al., 2008; Sonnenberg et al., 2011). T-bet-expressing
group 1 ILCs protect against bacteria such as Helicobacter
typhlonius (Powell et al., 2012) and intracellular pathogens
such as Salmonella enterica in an IFN-g-dependent manner
(Klose et al., 2013).
Recently we identified a human ILC1 subset that like ILC2
and ILC3 expressed high amounts of the IL-7 receptor a-sub-
unit (CD127) and the C-type lectin CD161. CD127+ ILC1 lacked
c-Kit and NKp44, which are expressed on all ILC3 and a subset
of ILC3, respectively. Another group identified a distinct subset
of group 1 ILCs, which were located in the intestinal epithelium
(Fuchs et al., 2013). These ILC1 expressed the epithelial hom-
ing integrin CD103 and only low amounts of CD127. The rela-
tionship between these CD103+ ILC1 and CD127+ ILC1 is
unclear. Here we compared the CD103+ ILC1 and CD127+
ILC1 in more detail.
Previously, we and others demonstrated that prolonged expo-
sure to type 1 polarizing cytokines induced a change of ILC3 into
c-Kit NKp44 ILC1. This was accompanied by downregulating
RORC, which was inversely proportional to the upregulation of
TBX21 and the production of IFN-g (Bernink et al., 2013; Vonar-
bourg et al., 2010). In line with this observation, individuals with
Crohn’s disease—a typical type 1 inflammatory disease—dis-
played a reduced frequency of group 3 ILCs in inflamed ileal
resection specimen, whereas group 1 ILCs were present in a
considerably higher frequency compared to patients without in-
testinal inflammation (Bernink et al., 2013).
Here we addressed the question whether IFN-g-producing
group 1 ILCs have the potential to differentiate toward IL-22-pro-
ducing ILC3. We demonstrated both in vitro and in vivo that hu-
man CD127+ group 1—but not CD103+ ILC1 or cNK cells—can
differentiate into ILC3, depending on the cytokines they are
exposed to, a process which is dependent on the transcription
factor RORgt. Furthermore, we demonstrated that the gut
metabolite retinoic acid (RA) accelerates transition of CD127+
ILC1 to IL-22-producing ILC3, and we identified RA-producing
CD103+ dendritic cells (DCs) as a physiological source that could
drive ILC differentiation and maintenance of ILC3.
RESULTS
CD127 and CD103 Define Distinct ILC1 Subsets
Human group 1 ILCs comprise a heterogeneous population of
IFN-g-producing effector cells, including conventional natural
killer (cNK) cells and two populations of ILC1. The first ILC1 sub-
set described by our group (Bernink et al., 2013) expresses high
amount of CD127 (the IL-7Ra chain), and is referred to as
CD127+ ILC1. The ILC1 subset described by Fuchs et al.
(2013) expresses CD103 (an intergrin aE subunit), which in asso-
ciation with b7 may play a role in homing of intraepithelial lym-
phocytes. This ILC1 subset is therefore referred to as CD103+
ILC1. In order to obtain more insight into the functional differ-
ences between CD127+ and CD103+ ILC1, we first compared
the phenotype and tissue distribution of the two ILC1 subsets
in human palatine tonsils, ileum, and mesenteric lymph node.
CD103+ ILC1, which could be distinguished from CD127+ ILC1
by the expression of CD56, NKp44, and CD103 were detected
in tonsil and ileum, but not in mesenteric lymph node (Figure 1A).
The frequencies of CD127+ and CD103+ ILC1 subsets in tonsils
were similar, but were less compared to NKp44+ and NKp44
ILC3 (Figure 1A). In the ileum, the CD103+ ILC1 were found in
the epithelium as documented before (Fuchs et al., 2013),
whereas the CD127+ ILC1 were present in the lamina propria
(Figure 1A). Compared to CD127+ ILC1, CD103+ ILC1 expressed
very little CD127 if at all (Figure 1B). CD103+ ILC1 from tonsils ex-
pressed CD94 and are heterogeneous for CD160, whereas
CD127+ ILC1 were negative for both markers (Figure 1B). Both
ILC1 subsets expressed CD161, but CD103+ ILC1 showed
much lower expression compared to CD127+ ILC1 (Figure 1B).
Like CD103+ ILC1, conventional cNK cells expressed CD56
and CD94 and were heterogeneous for CD160, but lacked
expression of CD103, and CD161 (Figure 1B).
We next analyzed the expression of transcription factors in
freshly isolated ILC subsets. Transcripts of the transcription fac-
tor RORgt (RORC) were undetectable in ex vivo isolated CD103+
ILC1, and low—but not absent—in CD127+ ILC1 compared to
NKp44 and NKp44+ ILC3 subsets (Figure 1C). TBX21, which
encodes for the transcription factor T-bet was expressed at
highest levels in CD103+ ILC1 and CD127+ ILC1 as comparedto both ILC3 subsets. The transcription factor Eomesodermin
(Eomes), which has been associated with cNK cells in mice
(Daussy et al., 2014; Gordon et al., 2012; Klose et al., 2014),
was highly expressed in CD103+ ILC1, but absent in all
CD127+ ILC1 and ILC3 subsets (Figure 1C). As expected, both
ILC1 subsets but not ILC3, expressed transcripts for IFNG,
which was most pronounced in CD103+ ILC1. IL22 transcripts
were highly expressed in the NKp44+ ILC3 subset. The transcrip-
tion factor arylhydrocarbon receptor (AHR) was expressed in all
ILC subsets, but highest in ILC3. Freshly isolated intestinal ILC
subsets showed a similar transcription factor expression profile
compared to their tonsil counterparts (Figure S1A).
In contrast to ex vivo isolated cNK cells, CD103+ and CD127+
ILC1 did not produce IFN-g in response to IL-15 alone as
measured by enzyme-linked immunosorbent assay (ELISA) (Fig-
ure 1D). Combined stimulation with IL-15 and IL-12 resulted in a
robust IFN-g response in all ILC1 subsets, which was most pro-
nounced in cNK cells. Stimulation with the pro-inflammatory cy-
tokines IL-12 plus IL-18 induced a similar response in all group 1
ILC subsets and was higher compared to stimulation with IL-12
plus IL-15.
Together, these data demonstrate that in addition to cNK
cells, two distinct human IFN-g producing group 1 ILC subsets
are present in the tonsil and ileum, which have the ability to
respond to the pro-inflammatory cytokines IL-12, IL-15, and
IL-18 ex vivo.
When comparing the ILC composition of fetal intestine to that
of non-inflamed and inflamed resection specimens from patients
that suffer from Crohn’s disease, we observed that CD127+ ILC1
in fetal intestines, which were not yet colonized with commensal
bacteria, were very low in frequency, and we did not observe any
CD103+ ILCs (Figure 1E; Figure S1B). Furthermore, we observed
that fetal intestinal NKp44 ILC3 expressed CD103, whereas this
marker was restricted to CD103+ ILC1 in adult gut and tonsils
(Figure S1C). The frequency of CRTH2+ group 2 ILCs in the fetal
intestines decreased in post-natal intestinal tissues. Further-
more, whereas in adult non-inflamed intestinal resection spec-
imen the frequencies of CD103+ ILC1 and CD127+ ILC1 were
the same, lamina propria CD127+ ILC1 expanded dramatically
in inflamed ileum resected from Crohn’s disease patients, out-
numbering intraepithelial CD103+ ILC1, which expanded less
than 2-fold (Figure 1E; Figure S1D). No significant changes in fre-
quency were observed for cNK cells between non-inflamed and
inflamed Crohn’s ileum (Figure S1E).
Together, these data confirm that CD103+ ILC1 are restricted
to the intraepithelial compartment (Fuchs et al., 2013), whereas
CD127+ ILC1 are found within the lamina propria. Furthermore,
CD127+ ILC1 outnumbered CD103+ ILC1 in inflamed gut tissues
of Crohn’s disease patients.
IL-23 and IL-1b Are Sufficient to Drive Differentiation of
CD127+ ILC1 toward ILC3
Differentiation of ILC3 toward IFN-g-producing CD127+ ILC1 un-
der influence of IL-12may contribute to the increase in frequency
of CD127+ ILC1 in inflamed mucosal tissues as seen in the in-
flamed intestines of individuals with Crohn’s disease (Bernink
et al., 2013; Vonarbourg et al., 2010). We then asked whether
IFN-g-producing ILC1 have also the potential to differentiate to-
ward IL-22 producing ILC3. To address this question, we sortedImmunity 43, 146–160, July 21, 2015 ª2015 Elsevier Inc. 147
Figure 1. Phenotype, Function, and Distribution of CD127+ and CD103+ ILC1 in Human Tonsil, Intestine, and Mesenteric Lymph Node
(A) Flow cytometric analysis of the expression of CD103+ ILC1 andCD127+ ILC1 in freshly isolated tonsil mononuclear cells, which are depleted from T cells (CD3)
and B cells (CD19) by magnetic bead-based separation, in freshly isolated intestinal epithelial cell (IE) and lamina propria (LP) fraction of resection specimen, and
freshly mesenteric lymph nodes (MLN). Subsets were gated on CD3 and CD45+ followed by gating on either CD56, CD103, and NKp44 for CD103+ ILC1, or
(legend continued on next page)
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Figure 2. IL-2, IL-23, and IL-1b Drive ILC3 Differentiation
(A) Purified CD127+ ILC1, NKp44 ILC3, NKp44+ ILC3, CD103+ ILC1, and cNK cells from tonsil were cultured for 4 days either with IL-2 and IL-12 or with IL-2, IL-
23, and IL-1b. Cells were phenotyped for the expression of c-Kit and NKp44. Numbers in quadrants indicate percent cells in each. Data shown is representative of
4 experiments.
(B) Expression of intracellular IFN-gmeasured by flow cytometry of either IL-2 and IL-12 (dashed line) or IL-2, IL-1b, and IL-23 (black line) cultured subsets in (A),
following stimulation with PMA plus ionomycin. Data shown is representative of 3 experiments.
(C) Expression of intracellular IL-22 measured by flow cytometry of either IL-2 and IL-12 (dashed line) or IL-2, IL-1b, and IL-23 (black line) cultured subsets in (A),
following stimulation with PMA plus ionomycin. Data shown is representative of 3 experiments.CD127+ ILC1, NKp44 ILC3, NKp44+ ILC3, CD103+ ILC1, and
cNK cells (Figure 2A, left column), and cultured these cells for
4 days in the presence of feeder cells with IL-2 and IL-12, or
IL-23, and IL-1b. As documented previously (Bernink et al.,selecting for Lin (CD1a CD3 CD14 CD19 CD94 CD34 CD123 TCRab
NKp44 and c-Kit for CD127+ ILC1, both indicated in blue box. Numbers in gates
subsets in tissues is quantified in bar diagrams as percentage (%) of the total CD
least 15 experiments, with one to two donors each, and intestinal data is represe
(B) Flow cytometric analysis of CD127+ ILC1 (black line), CD103+ ILC1 (dashed l
used is as in Figure 1A. Data shown is representative of at least 4 experiments.
(C) Expression of RORC, TBX21, IL22, AHR, IFNG, and EOMES in the CD127+ IL
tonsils, presented relative to the expression of ACTB (which encodes b-actin). Da
each.
(D) IFN-g-production by CD127+ ILC1 (black), and CD103+ ILC1 (white), and cNK c
IL-18.
(E) Mean frequency (as percentage of total ILCs per sample) of CD103+ ILC1, CD
(N = 12), non-inflamed control intestine (N = 6), and Crohn’s disease intestine (N
*p < 0.05, **p < 0.01 (ANOVA). Error bars (A, C, D) represent SEM.2013; Cella et al., 2010), IL-2, IL-23, and IL-1b maintained the
ILC3 phenotype, and promoted the acquisition of NKp44.
Furthermore, IL-2 and IL-12 was sufficient to induce differentia-
tion of NKp44 and NKp44+ ILC3 toward CD127+ ILC1 (Bernink TCRgd BDCA2 FcεR1; Table S1), CRTH2 and CD161+, CD127+, and
(outlined areas) or quadrants indicate percent cells in each. Distribution of ILC1
45+ CD3 lymphocyte population. Data shown for tonsil is representative of at
ntative of at least 6 experiments, one donor each.
ine), and cNK cells (gray filled) of indicated surface molecules. Gating strategy
C1, NKp44 ILC3, NKp44+ ILC3, and CD103+ ILC subsets of freshly isolated
ta shown is combined data of at least 3 experiments, each with 1 to 2 donors
ells (gray), cultured for 4 days, either alone or IL-15 and/or IL-12, and IL-12 with
127+ ILC1, CRTH2+ ILC2, NKp44 ILC3, and NKp44+ ILC3 within fetal intestine
= 6). In these experiments IE and LP fractions were combined before analysis.
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et al., 2013), and CD127+ ILC1 cultured in the presence of IL-2
and IL-12 maintained their phenotype (Figure 2A). Although
CD127+ ILC1 showed only a modest expression of IL-1R and
IL-23R compared to ILC3 (Figure S2), CD127+ ILC1 differenti-
ated toward ILC3 when cultured with IL-1b, IL-2, and IL-23 (Fig-
ure 2A). As a consequence, CD127+ ILC1 lost their potential to
produce large amounts of IFN-g, and instead started to produce
IL-22 (Figures 2B and 2C). Neither CD103+ ILC1 nor cNK cells
differentiated into ILC3 or produced IL-22 (Figures 2A–2C).
IL-22 and IL-17 production is restricted to lymphocytes that
express the transcription factor RORgt (Ivanov et al., 2006),
whereas IFN-g production is associated with high expression
of the transcription factor T-bet (Lazarevic et al., 2011). Given
the plasticity of the CD127+ ILC subsets in their cytokine expres-
sion pattern, we asked whether the transcription factor program
adapted accordingly. As such, we purified ILC subsets from ton-
sils and intestinal resection specimens and cultured these cells
for 4 days in the presence of feeder cells with IL-2 and IL-12,
or IL-2 IL-23 and IL-1b (Figures S3A–S3F). Indeed, NKp44+
ILC3 lost their RORgt expression upon exposure to IL-2 and
IL-12, whereas T-bet was upregulated (Figures S3A and S3B).
Also, we observed a change into an ILC3-like transcription factor
profile in CD127+ ILC1 when exposed to IL-2, IL-23, and IL-1b
(Figures S3A and S3B). Notably, neither in ILC3 nor in CD127+
ILC1 we observed Eomes (Figure S3C). This was in sharp
contrast to cNK cells and CD103+ ILC1, which did not express
RORgt, but rather maintained or enhanced their expression of
T-bet and Eomes (Figures S3C and S3F).
The observation that CD127+ ILC1 acquire phenotypic and
functional features of ILC3 may be the result of outgrowth of a
small number of ILC3 contaminating the purified ILC1. In that
case, the ILC3 should have undergone many cell divisions. To
address this, we labeled sorted CD127+ ILC1 with a cell tracer
dye and cultured them in the presence of IL-2, IL-23, and IL-
1b. Electronic gating on cells that expressed high amounts of
the cell tracer, and thus did not proliferate, revealed that these
cells expressed c-Kit and NKp44, indicating that the non-prolif-
erated fraction of CD127+ ILC1 differentiated toward ILC3 (Fig-
ure 3A). This observation argues against the possibility that
outgrowth of contaminating ILC3 in CD127+ ILC1 cultures ac-
counted for the observed phenotype. Furthermore, we did not
detect any difference in viability between the non- and prolifer-
ating cell fractions (Figure 3B). Further supporting our hypothe-
sis, we sorted out ILC3-derived ILC1 and observed that these
cells could re-differentiate toward ILC3 in the in the presence
of IL2, IL-23, and IL-1b (Figure S4).
To further confirm that the CD127+ ILC1 can differentiate to
ILC3, we generated clones of purified ILC1 (>97%) in the pres-
ence of feeder cells and IL-2, IL-1b, and IL-23. No difference
was observed in the plating efficiencies between the two ILC3
populations and ILC1 under these conditions (Figure 3C). The
burst size after 14 days of culture was on the average 4,000 cells
per well (Figure 3D), allowing for a phenotypic evaluation of
the progeny of the individual ILC1. Most ILC1-derived clones
showed a heterogeneous phenotype as exemplified in the left
panel of Figure 3E; the right panel shows an overview of the dis-
tribution of nine individual cloneswithin the progeny of one single
cell. We observed cells with a phenotype of ILC1, NKp44 ILC3,
and NKp44+ ILC3 (Figure 3E). In addition, we observed clones150 Immunity 43, 146–160, July 21, 2015 ª2015 Elsevier Inc.that were partly NKp44+ c-Kit. Cells with a similar phenotype
were also observed in ex vivo isolated ILCs (Bernink et al.,
2013) and have yet to be characterized in more detail. The
different phenotypes we observed within a clone correlated
with different functional capacities, because c-Kit+ cells isolated
from the progeny of a single ILC1 producedmainly IL-22 and little
IFN-g, whereas c-Kit NKp44 cells isolated from the same cell
samples produced IFN-g and little IL-22 (Figure 3F). These data
support the notion that a sizeable fraction of CD127+ ILC1 can
differentiate into IL-22 producing ILC3 in the presence of the cy-
tokines IL-2, IL-23, and IL-1b.
ILC1 Differentiate toward ILC3 In Vivo
Previously, we demonstrated that CD127+ ILC1 accumulated at
the onset of intestinal inflammation in mice that were reconsti-
tuted with a human immune system (HIS) (Bernink et al., 2013).
In order to evaluate whether the observed ILC1 to ILC3 differen-
tiation in vitro also occurred in humanized mice without inflam-
mation, we engrafted sub-lethally irradiated lymphopenic mice
(NOD SCID IL2GC/; NSG) with human hematopoietic stem
cells (HIS-mice). First we analyzed the ILC1 and ILC3 composi-
tion in blood, spleen, lung, small intestine, and colon, which
were reconstituted on average up to 80% with human cells at
the age of 8 weeks (Figures 4A and 4B; Figure S5A). Next, we in-
jected humanized mice intravenously (i.v.) with expanded ILC1
as described previously (Bernink et al., 2013), which were
labeled with a cell tracer dye (Figure S5B). This allowed us to
trace the fate of ILC1 in vivo under homeostatic conditions. An-
alyses of blood, spleen, liver, lung, small intestine and colon re-
vealed that cell tracker-positive ILCs were clearly detectable in
all organs 4 days after injection (Figure 4C; Figure S5B). Interest-
ingly, the ILC distribution-profile of cell tracer-positive ILCs
is similar to the human ILC profile derived from the injected
hematopoietic stem cells (Figure 4B), which was particularly
emphasized in the small intestine, as also NKp44+ ILC3 were
detectable (Figure 4D).
ILCs inmice and humans are very similar in functional respects
although phenotypic differences are obvious. It has been docu-
mented also in mouse that ILC3 can lose RORgt and upregulate
T-bet and their capacity to produce IFN-g (Cella et al., 2010; Vo-
narbourg et al., 2010). Based on our findings, we expected that
these murine ILC3-derived ILC1 (also called ex-RORgt+ ILC3)
can differentiate back to ILC3 under homeostatic conditions.
To examine this, we reconstituted lymphopenic mice (Rag2/
Il2rg/) with murine NKp46+ NK1.1+ RORgt-fate-map (fm)+
ILC3, which had downregulated RORgt expression (ex-RORgt+
ILC3) (Klose et al., 2013) (Figure S5C). Analysis of small and large
intestine 6 weeks after injection revealed that, ILC3-derived ILC1
upregulated RORgt expression (Figure 4E). Together, these data
indicate that in the absence of inflammation, CD127+ ILC1 can
switch toward ILC3 in vivo.
Retinoic Acid Accelerates ILC3Differentiation and IL-22
Production
The vitamin A metabolite retinoic acid (RA) has recently been re-
ported to enhance IL-22 production by ILC3 inmice (Mielke et al.,
2013). Here we investigated whether RA contributes to the differ-
entiation of ILC1 toward ILC3. The subunits for the receptor for
RA, retinoic acid receptor a (RARA), g (RARG), and RXRG were
Figure 3. CD127+ ILC1 Clones Give Rise to IL-22 Producing ILC3 Subsets
(A) Flow cytometry of purified CD127+ ILC1 from tonsil, stimulated for 7 days with IL-2 IL-23 IL-1b, and stained with a proliferation dye. Numbers above bracketed
lines indicate percent of non-dividing cells and after first division, followed by phenotyping for the expression of c-Kit and NKp44. Numbers in quadrants indicate
percentage cells in each. Data shown is representative of 3 experiments.
(B) CD127+ ILC1 sorted from tonsil have been cultured for 5 days with IL-2, IL-23, and IL-1b. Non-proliferating cells (dashed line) and proliferating cells (black line)
were stained with a live/dead marker.
(C) Cloning efficiency of CD127+ ILC1, NKp44 ILC3, and NKp44+ ILC3 was tested in cultures with 1, 4, and 8 cells per well with IL-2, IL-23, and IL-1b, and feeder
cells for 14 days.
(D–F) Clonal burst sizes of two independent experiments were calculated based on the cloning efficiency assay. (E) Phenotyping and quantification of the
expression of c-Kit andNKp44 in expandedCD127+ ILC1 clones. (F) IL-22 and IFN-g production of clone 3, 4, and 5 derived ILC1 and ILC3 fractions. Error bars (C,
D, F) represent SEM.readily detectable in freshly isolated CD127+ ILC subsets (Fig-
ure 5A), suggesting that these cells are responsive to RA. Purified
NKp44 ILC3 and CD127+ ILC1 stimulated with the combinationwith IL-2, IL-1b, and IL-23 upregulated NKp44, and this effect
was further enhanced by the addition of RA (Figure 5B), suggest-
ing that RA accelerated differentiation. In line with these results,Immunity 43, 146–160, July 21, 2015 ª2015 Elsevier Inc. 151
Figure 4. Expanded ILC1 Differentiate to ILC3 in NOD SCID IL2gc–/– (NSG) Mice that Were Engrafted with Human Immune Cells
(A) Gating strategy of human ILCs of the lamina propria mononuclear cells fraction of the large intestine in humanized mice. Cells were electronically gated on
lymphoid cells, followed by gating on human (h) CD45 cells. Then gating strategy was used as in Figure 1A.
(B) Using gating strategy as in Figure 4A, blood, spleen, lung, small intestine, and large intestine were analyzed for the expression of c-Kit and NKp44.
(legend continued on next page)
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weobserved that RAenhanced upregulation of RORgt in CD127+
ILC1 cultured with IL-2, IL-23, and IL-1b as compared to IL-2
alone (Figure 5C).
Next, we measured IL-22 protein by ELISA in cultures that
started with purified CD127+ ILC1. Culture with RA alone did
not result in any production of IL-22. However, when cultured
for 7 days in combination with IL-2, IL-23, and IL-1b, increased
amounts of IL-22 were found in the culture supernatants of
CD127+ ILC1, and further increased in the presence of RA (Fig-
ure 5D), indicating that following differentiation of ILC1 to
NKp44+ ILC3, these cells started to produce IL-22. RA did not
induce a notable production of IL-22 in either CD103+ ILC1 or
cNK cells (Figure S6). Cells cultured in the presence of RA
showed a reduced proliferating capacity (Figure 5E). Thus,
although RA enhanced differentiation of ILC1 into functional
ILC3, it also reduced expansion of the ILC3 pool.
Differentiation of CD127+ ILC1 to ILC3 Is Controlled by
RORgt
Given the plasticity among the CD127+ ILCs in terms of tran-
scription factor and cytokine expression profile, we asked
whether differentiation of CD127+ ILC1 to ILC3 was controlled
by the transcription factor RORgt. To address this question,
we cultured purified tonsil CD127+ ILC1 and ILC3 for 4 days
with IL-2, IL-23, and IL-1b in the presence or absence of
SR1001, a synthetic RORgt ligand, which induces suppression
of the receptor’s transcriptional activity (Solt et al., 2011).
SR1001 inhibited differentiation of CD127+ ILC1 to ILC3 com-
pared to the DMSO control, as reflected by their hampered up-
regulation of c-Kit and NKp44 and reduced IL-22 production,
whereas the cell number did not differ (Figures 6A and 6B).
SR1001 variably affected IL-22 production by NKp44 ILC3,
compared to the DMSO control as measured by ELISA (Fig-
ure 6B), but SR1001 did not substantially affect the ability of
ex vivo isolated NKp44+ ILC3 to produce IL-22.
Together, these data indicate that RORgt is important for the
differentiation from CD127+ ILC1 toward IL-22 producing ILC3
but may not be involved in IL-22 production after completion of
the differentiation process.
ILC Plasticity Is Instructed by Dendritic Cells
The finding that CD127+ ILC1 can differentiate into ILC3 raises
the question which cell type may induce this differentiation. We
examined the frequencies of HLA-DR+ CD11c+ dendritic cells
(DCs) in Crohn’s ileum compared to non-inflamed control. We
observed that a significantly greater proportion of DCs in the in-
flamed gut expressed CD14 and that the CD14 expression levels
were higher than on CD14+ DC from non-inflamed tissue (Fig-
ure 7A). While there was no detectable difference in the expres-(C) Humanized mice were retro-orbitally inoculated with expanded and with cell tr
Percentage of cell tracker positive ILCs compared to total hCD45 ILCs in analyze
indicating percentage of cell tracker positive ILCs per organ.
(D) Using gating strategy as in Figures 4A and 4C, blood, spleen, lung, small intes
Data shown is representative of 3 experiments, each with 2 humanized mice (1–
(E) Ex-RORgt+ ILC3 (defined as LinRORgt-fm+NKp46+NK1.1+) andNK/ILC1 (de
week old Rorc(gt)-CreTg 3 Rosa26R-YFP mice on a C57BL/6 background (H-2b
which were kept for 6 weeks under SPF conditions before analysis of RORgt expre
bars (C) represent SEM.sion of IL23A between CD14 and CD14+ DCs, the latter did
show increased expression of IL12A (Figure 7B), indicating a po-
tential role for these cells in the differentiation into CD127+ ILC1.
In order to investigate the differential potential of these two DC
subsets in promoting and maintaining the ILC1 phenotype, we
cultured CD127+ ILC1 or NKp44+ ILC3 in the presence of autol-
ogous CD14+ or CD14 DCs. CD127+ ILC1 maintained their
phenotype when cultured with CD14+ DCs but upregulated
c-Kit and NKp44 to adopt an ILC3 phenotype when cultured
with CD14 DCs. In contrast, NKp44+ ILC3 differentiated to
the CD127+ ILC1 phenotype in the presence of CD14+ DCs but
maintained their signature c-Kit and NKp44 expression when
cultured with CD14 DCs (Figure 7C). Similar results were also
obtained in an allogeneic setting in which fetal intestinal DCs
were co-cultured with freshly isolated tonsillar ILCs. In these ex-
periments, lipopolysaccharide (LPS) activated CD14+ DCs pro-
moted differentiation of NKp44+ ILC3 to CD127+ ILC1, whereas
CD14 DCs favored development of ILC3 (Figure S7A). In
contrast to intestinal CD14+ DCs, CD14 DCs are heteroge-
neous in their expression of CD103 (Figure 7D). As CD103+
DCs have been demonstrated to produce RA (Coombes et al.,
2007; Sanders et al., 2014), we asked whether CD103+ DCs
are sufficient to drive ILC3 conversion. To this end, we employed
a recently described in vitro monocyte derived DC (mDC)
culturing system (Bakdash et al., 2014). We cultured peripheral
blood derived CD14+ monocytes in the presence of GM-CSF
and IL-4 in the presence or absence of RA. Only mDCs cultured
in the presence of RA (RA-mDC) upregulated CD103 and started
toproduceRAbothunderbasal conditions (Bakdashet al., 2014),
as well as upon stimulation with LPS as measured by the activity
of the enzyme aldehyde dehydrogenase (ALDH), which drives
the conversion of retinaldehyde into RA (Figure S7B). As a control
we used diethylaminobenzaldehyde (DEAB), which inhibited
ALDH activity, and thereby the conversion of retinol to RA.
RA-mDC also expressed higher levels of IL23A transcripts
upon LPS or polyI:C stimulation as compared to mDC (Fig-
ure S7C). In contrast, mDC expressed higher IL12A transcripts
upon stimulation with either poly I:C or LPS compared to RA-
mDC (Figure S7C). In line with these findings we observed that
CD127+ ILC1 cultures with activated RA-mDC induced an
enhanced differentiation toward ILC3 compared to mDCs (Fig-
ure 7E). Together these in vitro experiments show that ILC3
have the capacity to differentiate into CD127+ ILC1 and vice
versa, depending on the milieu they are exposed to.
DISCUSSION
Group 2 and group 3 ILC subsets have been well characterized,
whereas group 1 ILCs are less clearly defined. Recently, we andacker labeled ILC1 (13 105 – 53 105 cells per mouse) 4 days before analysis.
d organs varied between 0% and 0.5%. Left, large intestine; right, bar diagram
tine, and large intestine were analyzed for the expression of c-Kit and NKp44.
3 donors each), and reconstituted cells are from 1 donor each.
fined as LinRORgt-fmNKp46+NK1.1+) (Figure S5C) were isolated from eight
), and were transferred intravenously into 8-week-old Rag2/ Il2rg/ mice,
ssion in small and large intestine. Ex-RORgt+ ILC3: N = 3; NK/ILC1: N = 2. Error
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Figure 5. RA Accelerates ILC3 Differentiation and IL-22 Production
(A) Expression of RARA, RARG, and RXRG of CD127+ ILC1 and ILC3 subsets, presented relative to the expression of ACTB (which encodes b-actin) of freshly
isolated CD127+ ILC1 NKp44 ILC3, and NKp44+ ILC3. Data shown is combined data of at least 3 experiments with 1 to 2 donors each.
(B) Freshly isolated CD127+ ILC1, and NKp44 ILC3, from tonsil are cultured for 4 days either with IL-2 IL-23, and IL-1b or with IL-2, IL-23, IL-1b, and retinoic
acid (RA). Cells were phenotyped for the expression of c-Kit and NKp44 and numbers in quadrants indicate percent cells in each. Data shown is
(legend continued on next page)
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Figure 6. CD127+ ILC1 Derived Differentiation to ILC3 Is Controlled by RORgt
(A) Freshly isolated CD127+ ILC1, NKp44 ILC3, and NKp44+ ILC3 from tonsil are cultured for 4 days with IL-2 IL-23, IL-1b, and RA in the presence of either
SR1001 or DMSO. Cells are phenotyped for the expression of c-Kit and NKp44. Numbers in quadrants indicate percentage cells in each. On the right, bar di-
agrams indicate absolute cell number and percentage of c-Kit+ NKp44+ cells of each subset cultured in either SR1001 or DMSO.
(B) IL-22-production by CD127+ ILC1, NKp44 ILC3, and NKp44+ ILC3, cultured as in 6a. Data shown is combined data of 3 experiments. *p < 0.05 (Mann-
Whitney test). Error bars (A, B) represent SEM.another research group identified human ILC subsets that
shared the capacity to produce IFN-g (Bernink et al., 2013;
Fuchs et al., 2013). These subsets were distinct from each other;
one expressed high amounts of CD127, whereas the other ex-
pressed the integrin CD103 and only low amounts of CD127.
Here we compared these two subsets side by side. We
confirmed that CD103+ ILC1 are located within the epithelium
of the intestine, whereas CD127+ ILC1 reside in the lamina prop-
ria. Both populations were present only in very low numbers in
fetal intestine, which suggests that colonization by microbiota
may trigger their appearance in the intestine. We found that
CD127+ and CD103+ ILC1 were equally distributed in both tonsil
and non-inflamed intestinal resection specimen. In inflamed
resection specimens of individuals with Crohn’s disease, we
observed a dramatic increase in frequency of CD127+ ILC1
whereas the proportions of CD103+ ILC1 also increased but to
a substantially lesser extent.
In mice a distinct subset of ILC1 has been recently character-
ized which also lacked Eomes but were NKp46+ Tbet+ and
RORgt-fm, meaning that these cells never expressed RORgt
during their development (Klose et al., 2014). This ILC1 subsetrepresentative of at least 4 independent experiments with 1 to 2 donors each
diagrams on the right.
(C) Freshly isolated CD127+ ILC1 from tonsil are cultured for 7 days with either IL-2
RA (dotted line), followed by intracellular staining for RORgt. Data shown is repre
(D) Il-22 production by CD127+ ILC1, cultured for 4 days with RA alone, with IL-2, I
experiments with 1 donor each.
(E) Flow cytometry of CD127+ ILC1 stimulated for 7 days with either IL-2 IL-23 IL-1
proliferation dye. Data shown is representative of 5 experiments with 1 donor eawas mainly present in the mucosal tissues, such as the intestine
(Klose et al., 2014). Although the human CD127+ ILC1 subset
described here also lack Eomes, they also lacked expression
of the natural cytotoxicity receptors (NCRs) NKp46 and
NKp44. CD103+ ILC1 have been described to express perforin
and granzymes, and mostly co-express Eomes and Tbet, and
therefore may represent a subset of cNK cells specifically
located in the epithelium. Thus the human cell types described
here are probably distinct from the mouse RORgt fate-map
ILC1 and the human equivalent of these cells has yet to be
indentified.
Previous studies in human and mouse systems have provided
evidence that ILC3, particularly in the intestine, have the ability to
upregulate T-bet and downregulate RORgt, both in vitro and
in vivo (Bernink et al., 2013; Klose et al., 2013; Vonarbourg
et al., 2010). Here we reported that human IFN-g-producing
CD127+ T-bet+ c-Kit NKp44 ILC1 can differentiate into IL-
22-producing NKp44+ ILC3. This differentiation was induced
by IL1b and IL-23, coincided with increased levels of RORgt
and decreased levels of T-bet and was amplified by RA. Since
RA has been shown to directly upregulate RORgt (van de Pavert. Percentage of c-Kit+ NKp44+ cells and cell numbers are indicated in bar
(gray line), with IL-2, IL-23, and IL-1b (black line), or with IL-2, IL-23, IL-1b, and
sentative of 2 experiments with 2 donors each.
L-23, and IL-1b, or IL-2, IL-23, IL-1b, and RA. Data shown is representative of 3
b (dotted line) or IL-2 IL-23 IL-1b, and RA (black line), which were stained with a
ch. *p < 0.05 (Mann-Whitney test). Error bars (A, B, D) represent SEM.
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Figure 7. Intestinal Dendritic Cells (DCs) Control Differentiation of CD127+ ILC1 toward ILC3
(A)Gating strategyof intestinal DCs.Cellswerepre-gatedonCD3, CD45+ (data not shown), followedbygatingonHLA-DRandCD11c. Fetal gut, non-inflamed ileal
(control), andCrohn’s disease ileal DCs, andMLNDCswere analyzed for the expression of CD14 and quantified in bar diagrams. ***p < 0.001 (analysis of variance).
(B) Expression of IL23A and IL12A in freshly isolated ileal CD14+ and CD14 DC subsets, relative to the expression of ACTB (which encodes for b-actin). Data
shown is combined data of 3 independent experiments with 1 donor each. *p < 0.05 (Mann-Whitney test).
(C) Autologous co-culture assay between either freshly isolated intestinal CD14 or CD14+ DCs (isolated according to gating strategy in A) and CD127+ ILC1 and
ILC3 (isolated according to gating strategy in Figure 1A). Cells were cultured for 4 days. Numbers in quadrants indicate percentage cells in each. On the right, bar
diagrams indicate percentage of c-Kit+ NKp44+ cells.
(D) CD103 expression on CD14+ and CD14 intestinal DCs. On the right the bar diagram in which the percentage is quantified. ***p < 0.001 (Mann-Whitney test).
(E) In vitro generated mDC and RA-mDCs (as shown in methods) were stimulated with LPS and co-cultured with freshly isolated tonsil CD127+ ILC1, NKp44
ILC3, NKp44+ ILC3 for 4 days. Cells were analyzed for the expression of c-Kit and NKp44. Numbers in quadrants indicate percentage cells in each. Data shown
is representative of at least 3 independent experiments. On the right the bar diagram in which the percentage is quantified. *p < 0.05 (Student’s t test). Error bars
(A–E) represent SEM.
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et al., 2014), those findings raised the possibility of an involve-
ment of RORgt in this process. This notion is reinforced by the
finding that SR1001, an antagonist binding to the ligand binding
domain of RORgt (Solt et al., 2011), inhibited ILC3 differentiation.
Not only the frequency of NKp44+ ILC3, but also the accumula-
tion of IL-22 during the differentiation process was reduced by
the RORgt inhibitor. Importantly, SR1001 did not inhibit IL-22
production by ex vivo isolated NKp44+ ILC3, suggesting that
the reduction of IL-22 production in the ILC1 differentiation cul-
tures was the result of inhibition of the differentiation process
of ILC1 into ILC3 and not of the effector function of ILC3 after
completion of the differentiation process. However, it should
be noted that not all CD127+ ILC1 differentiated toward ILC3 in
the presence of IL-2, IL-1b, and IL-23. Between 2%–15% of
the cells kept their ILC1 phenotype. Whether these cells consti-
tute a distinct subset or whether a certain equilibrium is main-
tained between the subsets remains an open question and
needs to be further investigated.
Using HIS-mice, we previously observed that CD127+ ILC1
expanded in frequency promptly upon inflammation in the gut
(Bernink et al., 2013). We proposed that the accumulation of
ILC1 under those conditions is the result of a rapid inflamma-
tion-induced differentiation of NKp44+ ILC3, which dominate un-
der homeostatic conditions, into ILC1. This conversion was
dependent on IL-12 (Bernink et al., 2013; Vonarbourg et al.,
2010). Gut inflammation triggers the influx of IL-12 producing
phagocytes (Goldszmid et al., 2012; Neurath, 2014; Schulthess
et al., 2012). In line with those findings we observed in intestinal
resection specimen from people with Crohn’s disease an
elevated frequency of IL12 expressing CD14+ DCs compared
to non-inflamed control, and ex vivo isolated CD14+ DC cultures
in the presence of NKp44+ ILC3 were sufficient to drive ILC3 to
ILC1 differentiation. CD14 DCs dominate under homeostatic
conditions, and these cells were sufficient to drive ILC1 to ILC3
differentiation. Our observation that human ILC1 can also differ-
entiate into ILC3 in reconstituted HIS mice and that mouse ILC3-
derived ILC1 (or ex-ILC3) differentiate into ILC3 in lymphopenic
mice, raises the possibility that after resolution of inflammation
the ‘‘inflammatory’’ IFN-g-producing CD127+ ILC1 revert to ‘‘ho-
meostatic’’ IL-22-producing ILC3. Further evaluation of the
CD14- population revealed approximately 25% of these cells ex-
pressed CD103, which marks an RA-producing tissue resident
DC population. Direct comparison of monocyte-derived DCs
and RA-producing CD103+ DCs (Bakdash et al., 2014) revealed
that the latter were superior in driving ILC1 to ILC3 conversion
compared to the mDCs. Thus, DCs respond differently to envi-
ronmental cues, which enable them to instruct the ILCs.
Several studies in mice support the idea that DCs are impor-
tant in instructing ILCs. In one study, it was demonstrated that
basal production of Il-1b by a subset of gut-resident macro-
phages in mice was essential for ILC3 homeostasis locally and
in MLN. Crosstalk between these macrophages and ILC3 in-
structed CD103+ DCs to produce RA, which in turn contributed
to intestinal homeostasis (Mortha et al., 2014). Another study
demonstrated that CD103+ DCs are a cellular source of IL-23,
which have been demonstrated to interact and activate ILCs in
a transient manner (Kinnebrew et al., 2012).
Our data suggest that RA is an important regulator of ILC1
to ILC3 conversion. RA is present in high concentrations inthe gastrointestinal tract (Veldhoen and Brucklacher-Waldert,
2012). Epithelial-derived RA has been shown to influence pro-
cesses of immune cells located in the lamina propria. For ex-
ample, RA drives differentiation of monocytes toward CD103+
DCs, which acquired a tolerogenic phenotype and thereby able
to drive regulatory T cell differentiation (Iliev et al., 2009). RA
also has a direct effect on mouse ILC3 by promoting the upregu-
lation of IL-22 (Mielke et al., 2013), and in another study it was
demonstrated that the gut-resident ILC composition is directly
influenced by RA, favoring ILC3 over ILC2 (Spencer et al.,
2014). In line with these reports, we observed in our in vitro cul-
tures that RA, in combination with IL-2, IL-23, and IL-1b, induced
human ILC3 differentiation and enhanced IL-22 production. This,
together with the notion that high titers of RA are readily pro-
duced by epithelial cells and lamina propria-resident CD103+
DCs, may explain our observation that adult gut-resident
CD127+ ILCs predominantly comprised the NKp44+ ILC3 com-
partment and lacked CRTH2+ ILC2. These NCR+ ILC3 ex-
pressed high levels of IL22 under homeostatic conditions
compared to NKp44 ILC3 and ILC1, possibly in order to main-
tain the integrity of the epithelial barrier during homeostasis
(Sonnenberg and Artis, 2012).
We found in intestinal resection specimen of Crohn’s disease
patients an increased frequency of IFN-g producing CD127+
ILC1, which was inversely proportional to the reduced frequency
of NKp44+ ILC3. Intestinal inflammation, such as Crohn’s dis-
ease, is accompanied by an influx of pro-inflammatory IL-12 pro-
ducing phagocytes at the site of infection (Goldszmid et al.,
2012), which may drive the differentiation of ILC3 toward
CD127+ ILC1. IFN-g in turn, has been reported to orchestrate
the replacement of resident mononuclear phagocytes by circu-
lating pro-inflammatory monocytes (Goldszmid et al., 2012), re-
inforcing the pro-inflammatory milieu at the site of infection.
Furthermore, it was reported that IFN-g signals directly on Pan-
eth cells in the intestinal crypts, instructing them to release anti-
microbial compounds, which was coupled to the extrusion and
death of Paneth cells (Farin et al., 2014). Concordantly, pro-
longed IFN-g responses do harm the host, resulting in severe
gut inflammation (Buonocore et al., 2010; Klose et al., 2014; Vo-
narbourg et al., 2010). Therefore, it is tempting to speculate that
persistently increased numbers of ILC1 contribute to the disease
process. If this is the cas,e it might be possible that enforcing dif-
ferentiation of these ILC1 to ILC3 may have a therapeutic effect
in Crohn’s disease. In this respect, it is noteworthy that ILC1 iso-
lated from surgical specimens of Crohn’s disease patients also
convert to NKp44+ ILC3.
Taken together, an efficient mechanism presents itself by
which ILC can quickly adapt to changes inflicted by pathogens
without the need of recruiting new cells from the circulation.
Furthermore, the identification of environmental cues and tran-
scription factors that drive this plasticity may be used to develop
future targets for potential therapeutic interventions.EXPERIMENTAL PROCEDURES
Tissue Collection
All tissues were collected after subjects provided informed consent, with
approval of tissue-specific protocols by the Medical Ethical Committee of
the Academic Medical Centre, Amsterdam. Tonsils were obtained fromImmunity 43, 146–160, July 21, 2015 ª2015 Elsevier Inc. 157
pediatric tonsillectomies. Inflamed intestinal ileum of patients with Crohn’s dis-
ease was freshly obtained and processed after surgical resection. Non-in-
flamed ileum, referred to as ‘‘non-inflamed control,’’ was collected after surgi-
cal resection of colon cancer, where the ileum was considered unaffected.
Subjects were excluded if they had undergone chemo- or radiotherapy before
resection. Patients’ age range is from 18 to 68 years. Human fetal tissues were
obtained from elective abortions at the Stichting Bloemenhove clinic in Heem-
stede, the Netherlands, upon on the receipt of informed consent. The use of
human abortion tissues was approved by the Medical Ethical Committee of
the AcademicMedical Center, Amsterdam. Gestational age, determined by ul-
trasonic measurement of the diameter of the skull or femur, ranged from 14 to
17 weeks.
Human Immune System Mice
CD34+ CD38 HSCs isolated from human fetal liver (0.23 105 – 23 105 cells)
were transplanted intrahepatically into sublethally irradiated (1.0 Gy) newborn
NSGmice (younger than 1 week of age). Peripheral blood was collected from a
facial vein every 3 to 4 weeks after transplantation to determine the kinetics of
human cell engraftment. At 2months of age, mice were retro-orbital inoculated
with approximately 1 3 105 – 5 3 105 expanded and cell tracker labeled
CD127+ ILC1 (as described in Bernink et al.). After 4 days, mice were sacrificed
and organs were harvested for analyses.
Transfer Experiments
ILC populations were prepared from 8-week-old Rorc(gt)-CreTg x Rosa26R-
YFP mice on a C57BL/6 background (H-2b) (as described in Vonarbourg
et al., 2010). Ex-RORgt+ ILC3 were defined as Lin RORgt-fm+ NKp46+
NK1.1+ cells and the NK/ILC1 population was defined as Lin RORgt-fm
NKp46+ NK1.1+ cells. Using a BD FACS Aria III cell sorter, cells were sorted
into Eppendorf tubes filled with 500 ml Dulbecco’s Modified Eagle Medium
(DMEM) supplemented with 10% FCS, 10mM HEPES, 1mM Sodium Pyru-
vate plus nonessential amino acids, 80 mM 2-Mercaptoethanol, 8 mg/ml
Glutamine, 100 U/ml Penicillin, 0.4 mg/ml Gentamicin, and 100 mg/ml
Streptomycin. Cells were subsequently washed in PBS and 8,000 cells
were transferred intravenously into 8-week-old Rag2/ Il2rg/ mice.
Mice were kept for 6 weeks under SPF conditions at which time they
were analyzed.
Isolation of Cells
Tonsil tissue was cut in small pieces and mechanically disrupted using the
Stomacher 80 Biomaster (Seward). Cell suspension was passed through a
70 mm cell strainer and mononuclear cells were isolated with Ficoll-Paque
Plus medium (GE Healthcare).
Intestinal lamina propria was incubated for 30minwith PBS containing 5mM
EDTA at 37C to separate epithelial cells from lamina propria cells. Lamina
propria was then cut into small pieces and digested for 30 min at 37C with
RPMI (GIBCO) containing Liberase TM (125 mg/ml). Cell suspensions were
filtered through a 70 mm nylon mesh, and intraepithelial and lamina propria
mononuclear cells were isolated with Ficoll-Paque Plus medium (GE Health-
care). In some experiments IEL and LP fractions were analyzed separately,
and in some experiments both fractions were combined before analysis.
Mesenteric lymph nodes were mechanically disrupted and were passed
through a 70 mm cell strainer and mononuclear cells were isolated with
Ficoll-Paque Plus medium.
Isolation of lamina propria lymphocytes (LPL) in mice was performed
as described in Sanos and Diefenbach (2010). In short: small intestines
were removed, Peyer’s patches were excised, and the intestines were
flushed with ice-cold PBS and cut longitudinally. Epithelium was dissociated
by incubation for 40 min at 37C in Hank’s Balanced Salt Solution
without Ca2+/Mg2+ (HBSS) with 5 mM EDTA and 10 mM HEPES and subse-
quent vortexing. Remaining tissue, containing LPL, was minced with a
scalpel and digested in HBSS (with Ca2+/Mg2+) containing Collagenase D
(0.5 mg/ml), DNase I (0.5 mg/ml), and Dispase (0.5 U/ml) for 1 hr at
37C under constant shaking. Cells were detached by thorough vortexing
and filtered through a 70 mM filter. Leukocytes were enriched using a
Percoll Gradient centrifugation. Cells were resuspended in PBS containing
2% FCS and stained for 30 min on ice with fluorochrome-conjugated
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The antibodies used to human and mice proteins are listed in Table S3. For
phenotypic analyses by flow cytometry, data were collected with an LSR-For-
tessa instrument (BD Biosciences). For sorting by flow cytometry an ARIA IIU
(BD Biosciences) was used. Data was analyzed with FlowJo software
(TreeStar). Peripheral blood and tonsil mononuclear cell samples were
depleted of T cells and B cells by labeling with FITC-conjugated anti-CD3
and anti-CD19 (described above) plus anti-FITC microbeads (Miltenyi).
Intracellular Cytokine Staining
Cell cultures were stimulated for 6 hr with PMA (10 ng/ml; Sigma) and ionomy-
cin (500 nM; Merck) in the presence of GolgiPlug (BD Biosciences) for the final
4 hr of culture. A Cytofix/Cytoperm kit (BD Biosciences) was used for cell per-
meabilization, staining, and subsequent washing. The following antibodies
were used: allophycocy- anin-conjugated IL-17 (BL168; BioLegend), and
phycoerythrin-conjugated anti-IL-22 (142928; R&D Systems) and anti-IFN-g-
pe-cy7 (B27; BD Bioscience). Data were acquired with an LSRFortessa instru-
ment (BD Biosciences) and analyzed with FlowJo software (TreeStar).
Quantative Real-Time PCR
RNA was isolated with NucleoSpin RNA XS kit (Macherey-Nagel) according to
the manufacturer’s protocol. Complementary DNA was synthesized with the
High-Capacity cDNA Archive kit (Applied Biosystems). PCR was done on a
LightCycler 480 Instrument II (Roche) with SYBR Green I master mix (Roche).
Primers sets used are shown in Table S2.
Cell Cultures and RORgt Inhibition
For short-term cultures (2 to 7 days), CD103+ ILC1, cNK cells, and Lin
CD127+ ILC populations were cultured in some experiments with or in
some experiments without irradiated allogeneic peripheral blood mononu-
clear cells (25 Gy), irradiated Epstein-Barr virus–transformed JY human B
cells (50 Gy), phytohemagglutinin (1 mg/ml; Oxoid), and IL-2 (100 U/ml;
Novartis) in Yssel’s medium (AMC; made in house) supplemented with
1% (vol/vol) human AB serum. For ILC3 polarization experiments IL-23
(50 ng/ml; R&D Systems), and IL-1b (50 ng/ml; R&D Systems), and in indi-
cated experiments retinoic acid (RA) (1 mM; Sigma-Aldrich) were supple-
mented to cultures. For ILC1 polarizing experiments IL-12 (50 ng/ml; R&D
Systems) was supplemented to cultures. Inhibition of RORgt was achieved
by the addition of the synthetic RORgt-ligand SR1001 (10 mM; Sigma-Aldrich)
to cell cultures with freshly isolated CD127+ ILC1 and ILC3, which were
cultured in the presence of IL-2 (10 U/ml; Novartis) IL-23 (50 ng/ml; R&D Sys-
tems), and IL-1b (50 ng/ml; R&D Systems and RA (1 mM; Sigma-Aldrich) and
RA (1 mM; Sigma-Aldrich).
Generation of mDC and RA-mDC
RA-mDCs andmDCswere generated as described in (Bakdash et al., 2014). In
brief, monocytes were isolated from PBMCs using density centrifugation, then
cultured for 6 days in IMDM (GIBCO) containing gentamicin (86 mg/l; Duchefa)
and 10% FCS (GIBCO), supplemented with GM-CSF (500 U/ml; Schering-
Plough) and IL-4 (10 IU/ml; Miltenyi Biotech, Bergisch Gladbach, Germany).
RA-DCs were generated in the additional presence of 1 mM of retinoic acid
(Sigma-Aldrich).
Aldefluor Assay
The ALDH activity of DCs was determined by the ALDEFLUOR staining kit
(Aldagen) following manufacturer’s instructions.
Cytokine Production
Freshly isolated CD103+ ILC1, CD127+ ILC1, and cNK cells (2,000 cells per
well in a 96-well plate) were stimulated for 4 days with combinations of IL-2
(10 U/ml; Novartis), IL-12 (50 ng/ml; R&D Systems), IL-18 (50 ng/ml; R&D Sys-
tems), IL-15 (50 ng/ml; R&D Systems). Cytokine production was measured by
enzyme-linked immunosorbent assay (ELISA). IFN-g (eBioscience) and IL-22
(R&D) were measured from supernatants of cultures.
Statistical Analysis
Statistical significancewas determinedwith ANOVA, Student’s t test, orMann-
Whitney test. Prism GraphPad software was used.
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